A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Ribociclib
Related studies linked through entity extraction aliases.
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
- Status
- RECRUITING
- Phase
- PHASE3
Study of Ribociclib Administered Concurrently With Postoperative Radiation Therapy in Patients With High-Risk, HR+/HER2- Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE1
Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE1
Study of AVZO-021 in Patients With Advanced Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
- Status
- RECRUITING
- Phase
- PHASE2
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE3
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Randomized Study Comparing the Immune Modulation Effect of Ribociclib, Palbociclib, and Abemaciclib in ER+/HER2- EBC
- Status
- RECRUITING
- Phase
- PHASE2
First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE1
Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Ribociclib in Combination With Non-steroidal Aromatase Inhibitors in Patients With Advanced Breast Cancer
- Status
- COMPLETED
- Phase
- N/A
Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE1
Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients
- Status
- RECRUITING
- Phase
- PHASE4
Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors
- Status
- TERMINATED
- Phase
- PHASE1